{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:05:15Z","timestamp":1788840315560,"version":"build-2803163510"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"DOI":"10.2146\/ajhp130049","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T17:13:14Z","timestamp":1374167594000},"page":"1301-1312","source":"Crossref","is-referenced-by-count":40,"title":["Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000\u201312"],"prefix":"10.1093","volume":"70","author":[{"given":"Catherine","family":"Staes","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, University of Utah, Salt Lake City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, University of Utah, Salt Lake City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanmarie","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Utah Health Care Hospital and Clinics, Salt Lake City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Allen","sequence":"additional","affiliation":[{"name":"Pin Oak Associates, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041607511257500_b1-0701301","unstructured":"Food and Drug Administration. Pharmacy compounding. www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/default.htm (accessed 2012 Nov 2)."},{"key":"2019041607511257500_b2-0701301","unstructured":"Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak investigation. www.cdc.gov\/hai\/outbreaks\/meningitis.html (accessed 2012 Nov 25)."},{"key":"2019041607511257500_b3-0701301","first-page":"842","article-title":"Multistate fungal meningitis outbreak\u2014interim guidance for treatment","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"issue":"2","key":"2019041607511257500_b4-0701301","first-page":"20","article-title":"Warnings for makers of compounded pain products","volume":"41","author":"Meadows","year":"2007","journal-title":"FDA Consum"},{"key":"2019041607511257500_b5-0701301","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.2012.47932","article-title":"Fungal meningitis from injection of contaminated steroids: a compounding problem","volume":"308","author":"Wilson","year":"2012","journal-title":"JAMA"},{"key":"2019041607511257500_b6-0701301","unstructured":"International Academy of Compounding Pharmacists responds to meningitis outbreak tied to compounding pharmacy. www.prnewswire.com\/news-releases-test\/the-international-academy-of-compounding-pharmacists-responds-to-meningitis-outbreak-tied-to-compounding-pharmacy-172725431.html (accessed 2013 Apr 19)."},{"key":"2019041607511257500_b7-0701301","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1542\/peds.108.2.471","article-title":"A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit\/hyperactivity disorder","volume":"108","author":"Romano","year":"2001","journal-title":"Pediatrics"},{"issue":"suppl","key":"2019041607511257500_b8-0701301","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jaci.2005.12.048","article-title":"Subpotency of a compounded budesonide for nebulization product in a patient with poorly controlled asthma","volume":"117","author":"Whelan","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2019041607511257500_b9-0701301","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/01.wnl.0000339380.23073.58","article-title":"4-Aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis","volume":"71","author":"Burton","year":"2008","journal-title":"Neurology"},{"key":"2019041607511257500_b10-0701301","first-page":"1050","article-title":"Deaths from intravenous colchicine resulting from a compounding pharmacy error\u2014Oregon and Washington, 2007","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"2019041607511257500_b11-0701301","unstructured":"Hundley\n              K\n            \n          . Lincare pharmacy runs afoul of Missouri regulators. www.sptimes.com\/2003\/04\/18\/Business\/Lincare_pharmacy_runs.shtml (accessed 2013 Apr 19)."},{"key":"2019041607511257500_b12-0701301","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajo.2011.11.023","article-title":"Avastin doesn\u2019t blind people, people blind people","volume":"153","author":"Gonzalez","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"2019041607511257500_b13-0701301","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/03639045.2012.662511","article-title":"Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection","volume":"38","author":"Chollet","year":"2012","journal-title":"Drug Dev Ind Pharm"},{"key":"2019041607511257500_b14-0701301","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9343(01)01032-4","article-title":"Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters","volume":"112","author":"Jones","year":"2002","journal-title":"Am J Med"},{"key":"2019041607511257500_b15-0701301","first-page":"1454","article-title":"Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?","volume":"30","author":"Goldman","year":"2004","journal-title":"Dermatol Surg"},{"key":"2019041607511257500_b16-0701301","unstructured":"Food and Drug Administration. Limited FDA survey of compounded drug products. www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/ucm155725.htm (accessed 2012 Nov 25)."},{"key":"2019041607511257500_b17-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: Med-South Pharmacy Inc. 28-Sep-07 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2007\/ucm076516.htm (accessed 2012 Nov 25)."},{"key":"2019041607511257500_b18-0701301","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2165\/11640850-000000000-00000","article-title":"Pharmacy compounding primer for physicians: prescriber beware","volume":"72","author":"Sellers","year":"2012","journal-title":"Drugs"},{"key":"2019041607511257500_b19-0701301","unstructured":"Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR) homepage. www.cdc.gov\/mmwr\/mmwr_wk\/wk_cvol.html (accessed 2012 Dec 14)."},{"key":"2019041607511257500_b20-0701301","unstructured":"Centers for Disease Control and Prevention. Epidemic Intelligence Service (EIS) Conference\u2014program archives for 2006\u20132012. www.cdc.gov\/EIS\/Conference\/Archive.html (accessed 2012 Nov 10)."},{"key":"2019041607511257500_b21-0701301","first-page":"310","article-title":"Notes from the field: multistate outbreak of postprocedural fungal endophthalmitis associated with a single compounding pharmacy\u2014United States, March\u2013April 2012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"2019041607511257500_b22-0701301","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/507336","article-title":"Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy","volume":"43","author":"Civen","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019041607511257500_b23-0701301","first-page":"404","article-title":"The cost of quality in pharmacy","volume":"6","author":"Kastango","year":"2002","journal-title":"Int J Pharm Compd"},{"key":"2019041607511257500_b24-0701301","unstructured":"Engel\n              J\n            \n          . Exophiala(Wangiella) dermatitidis fungal infection outbreak. http:\/\/epi.publichealth.nc.gov\/pdf\/en2002-4.pdf (accessed 2013 Apr 19)."},{"key":"2019041607511257500_b25-0701301","first-page":"1109","article-title":"Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy\u2014United States, July\u2013November 2002","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR"},{"key":"2019041607511257500_b26-0701301","unstructured":"Food and Drug Administration. Injectable drugs prepared by urgent care pharmacy. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm154503.htm (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b27-0701301","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1542\/peds.2005-2617","article-title":"Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state","volume":"118","author":"Held","year":"2006","journal-title":"Pediatrics"},{"key":"2019041607511257500_b28-0701301","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1086\/520664","article-title":"A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy","volume":"45","author":"Sunenshine","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019041607511257500_b29-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: Phar MEDium Services, LLC. 13-Apr-07 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2007\/ucm076357.htm (accessed 2012 Nov 25)."},{"key":"2019041607511257500_b30-0701301","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1086\/592968","article-title":"Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy","volume":"47","author":"Gershman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019041607511257500_b31-0701301","first-page":"269","article-title":"Pseudomonas bloodstream infections associated with a heparin\/saline flush\u2014Missouri, New York, Texas, and Michigan, 2004\u20132005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR"},{"key":"2019041607511257500_b32-0701301","first-page":"961","article-title":"Update: delayed onset Pseudomonas fluorescens bloodstream infections after exposure to contaminated heparin flush\u2014Michigan and South Dakota, 2005\u20132006","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR"},{"key":"2019041607511257500_b33-0701301","unstructured":"Food and Drug Administration. FDA issued nationwide alert on IV Flush brand of heparin or sodium chloride intravenous catheter flushes. www.fda.gov\/downloads\/ICECI\/EnforcementActions\/EnforcementStory\/EnforcementStoryArchive\/UCM091066.pdf (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b34-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: IV Flush, LLC. 04-August-05 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2005\/ucm075511.htm (accessed 2012 Dec 16)."},{"key":"2019041607511257500_b35-0701301","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1086\/598938","article-title":"An outbreak of postoperative gram-negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution","volume":"48","author":"Sunenshine","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019041607511257500_b36-0701301","unstructured":"Food and Drug Administration. Custom-Rx compounding pharmacy issues nationwide recall of trypan blue 0.06% ophthalmic solution. www.fda.gov\/Safety\/Recalls\/ArchiveRecalls\/2005\/ucm111889.htm (accessed 2012 Nov 11)."},{"key":"2019041607511257500_b37-0701301","article-title":"Outbreak of systemic inflammatory response syndrome linked to a compounding pharmacy\u2014Virginia, 2005","author":"Patel"},{"key":"2019041607511257500_b38-0701301","unstructured":"Food and Drug Administration. Compounded menopausal hormone therapy questions and answers. www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/ucm183088.htm (accessed 2012 Nov 11)."},{"key":"2019041607511257500_b39-0701301","unstructured":"Food and Drug Administration. Central Admixture Pharmacy Services, Inc.: urgent drug recall: all injectable products. www.fda.gov\/downloads\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/UCM164417.pdf (accessed 2012 Nov 11)."},{"key":"2019041607511257500_b40-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: B. Braun Medical Inc. 15-Mar-06 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2006\/ucm075828.htm (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b41-0701301","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3201\/eid1501.081054","article-title":"Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl","volume":"15","author":"Maragakis","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2019041607511257500_b42-0701301","article-title":"Serratia marcescens bloodstream infections in patients receiving total parenteral nutrition\u2014Alabama, 2011","author":"Gupta"},{"key":"2019041607511257500_b43-0701301","unstructured":"Food and Drug Administration. CDC and ADPH investigate outbreak at Alabama hospitals; products recalled. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm249099.htm (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b44-0701301","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","article-title":"An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab","volume":"153","author":"Goldberg","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"2019041607511257500_b45-0701301","article-title":"Histopathology of streptococcal endophthalmitis following intravitreal injection of bevacizumab: a series of seven cases","author":"Matthews","year":"2012"},{"key":"2019041607511257500_b46-0701301","article-title":"Streptococcal endophthalmitis associated with contaminated bevacizumab from a compounding pharmacy\u2014Florida, 2011","author":"Beau"},{"key":"2019041607511257500_b47-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: Infupharma, LLC. 7\/30\/12 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2012\/ucm317190.htm (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b48-0701301","unstructured":"Food and Drug Administration. FDA form 483 for Infupharma, LLC. www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofGlobalRegulatoryOperationsandPolicy\/ORA\/ORAElectronicReadingRoom\/UCM304256.pdf (accessed 2012 Dec 21)."},{"key":"2019041607511257500_b49-0701301","unstructured":"Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: Franck\u2019s Lab Inc., d.b.a. Franck\u2019s Compounding Lab. 7\/9\/12 (warning letter). www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2012\/ucm312645.htm (accessed 2012 Nov 10)."},{"key":"2019041607511257500_b50-0701301","unstructured":"Food and Drug Administration. Franck\u2019s Compounding Pharmacy sterile preparations: reports of fungal endophthalmitis, expanded recall. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm305592.htm (accessed 2012 Oct 28)."},{"key":"2019041607511257500_b51-0701301","unstructured":"Centers for Disease Control and Prevention. Multistate meningitis outbreak\u2014current case count. www.cdc.gov\/hai\/outbreaks\/meningitis-map-large_2013-01-07.html (accessed 2013 Mar 9)."},{"key":"2019041607511257500_b52-0701301","unstructured":"Committee on Energy and Commerce. Majority memorandum: hearing on \u201cThe fungal meningitis outbreak: could it have been prevented?\u201dhttp:\/\/energycommerce.house.gov\/sites\/republicans.energycommerce.house.gov\/files\/Hearings\/OI\/20121114\/HMTG-112-HHRG-IF02-20121114-SD001.pdf (accessed 2012 Dec 8)."},{"key":"2019041607511257500_b53-0701301","first-page":"839","article-title":"Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy\u2014United States, 2012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"2019041607511257500_b54-0701301","unstructured":"Food and Drug Administration. FDA form 483 for New England Compounding Center. www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofGlobalRegulatoryOperationsandPolicy\/ORA\/ORAElectronicReadingRoom\/UCM325980.pdf (accessed 2012 Dec 8)."},{"key":"2019041607511257500_b55-0701301","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMoa1212972","article-title":"Fungal infections associated with contaminated methylprednisolone in Tennessee","volume":"367","author":"Kainer","year":"2012","journal-title":"N Engl J Med"},{"key":"2019041607511257500_b56-0701301","unstructured":"Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak investigation: laboratory testing and results from the outbreak. www.cdc.gov\/hai\/outbreaks\/laboratory\/lab_testing_results.html (accessed 2012 Dec 16)."},{"key":"2019041607511257500_b57-0701301","unstructured":"Centers for Disease Control and Prevention. Update: multistate outbreak of fungal infections among persons who received injections with contaminated medication. http:\/\/emergency.cdc.gov\/HAN\/han00338.asp (accessed 2013 Jan 21)."},{"key":"2019041607511257500_b58-0701301","article-title":"Pharmaceutical compounding: sterile preparations (general information chapter 797)","volume-title":"The United States pharmacopeia, 35th rev., and The national formulary","year":"2012","edition":"30th ed"},{"key":"2019041607511257500_b59-0701301","unstructured":"Bronstein\n              D\n            \n            \n              Kandel\n              S\n            \n          . Meningitis outbreak fallout: whom can you trust?www.painmedicinenews.com\/ViewArticle.aspx?d=Clinical+Pain+Medicine&d_id=82&i=November+2012&i_id=906&a_id=22066 (accessed 2013 Apr 19)."},{"key":"2019041607511257500_b60-0701301","unstructured":"Centers for Disease Control and Prevention. Protect patients against preventable harm from improper use of single-dose\/single-use vials. www.cdc.gov\/injectionsafety\/cdcposition-singleusevial.html (accessed 2013 Jan 28)."},{"key":"2019041607511257500_b61-0701301","unstructured":"Food and Drug Administration. FDA renews nationwide alert on i.v. flush brand of heparin or sodium chloride intravenous catheter flushes in light of new contamination reports. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2005\/ucm108409.htm (accessed 2012 Nov 12)."},{"key":"2019041607511257500_b62-0701301","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.282.2.164","article-title":"Mandatory reporting of diseases and conditions by health care professionals and laboratories","volume":"282","author":"Roush","year":"1999","journal-title":"JAMA"},{"key":"2019041607511257500_b63-0701301","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/aje\/155.9.866","article-title":"Completeness of notifiable infectious disease reporting in the United States: an analytical literature review","volume":"155","author":"Doyle","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2019041607511257500_b64-0701301","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2105\/AJPH.2006.092700","article-title":"A comparison of the completeness and timeliness of automated electronic laboratory reporting and spontaneous reporting of notifiable conditions","volume":"98","author":"Overhage","year":"2008","journal-title":"Am J Public Health"},{"key":"2019041607511257500_b65-0701301","unstructured":"Utah Department of Health. Disease reporting resources and information. http:\/\/health.utah.gov\/epi\/report.html (accessed 2012 Dec 15)."},{"key":"2019041607511257500_b66-0701301","unstructured":"Centers for Disease Control and Prevention. Monitoring healthcare associated infections. www.cdc.gov\/HAI\/surveillance\/index.html (accessed 2012 Nov 3)."},{"key":"2019041607511257500_b67-0701301","unstructured":"Centers for Disease Control and Prevention. Voluntary recall of all Ameridose medical products. http:\/\/emergency.cdc.gov\/HAN\/han00332.asp (accessed 2012 Nov 12)."},{"key":"2019041607511257500_b68-0701301","unstructured":"Central Admixture Pharmacy Services. Products and services. www.capspharmacy.com\/Products.html (accessed 2012 Nov 19)."},{"key":"2019041607511257500_b69-0701301","unstructured":"Harris\n              M\n            \n            \n              Wong\n              W\n            \n          . Chicago technology venture capital scorecard for 2011. http:\/\/articles.chicagotribune.com\/2012-06-16\/business\/chi-chicago-technology-venture-capital-scorecard-for-2011-20120616_1_venture-capital-firestarter-fund-leo-capital (accessed 2013 Apr 19)."},{"issue":"suppl","key":"2019041607511257500_b70-0701301","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1177\/0148607111434779","article-title":"Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies","volume":"36","author":"Kastango","year":"2012","journal-title":"J Parenter Enteral Nutr"},{"key":"2019041607511257500_b71-0701301","unstructured":"Clinical\n              IQ\n            \n          . U.S. boards of pharmacy, sterile compounding laws, regulations and CE requirements map. http:\/\/clinicaliq.com\/797-state-survey (2013May16)."},{"key":"2019041607511257500_b72-0701301","unstructured":"Douglass\n              K\n            \n            \n              Kastango\n              ES\n            \n            \n              Cantor\n              P\n            \n            \n          . 2011USP <797> compliance study. www.pppmag.com\/article\/985\/ (accessed 2013 Apr 19)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/15\/1301\/28456263\/ajhp1301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T07:56:48Z","timestamp":1555401408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/15\/1301\/5112253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":72,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130049","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,8,1]]},"published":{"date-parts":[[2013,8,1]]}}}